HCAR1 | Hydroxycarboxylic acid receptor 1 | G-protein coupled receptors Predicted membrane proteins Transporters
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
HRASLS5 | HRAS-like suppressor family, member 5 | | ![](/images/42493/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42493/91853_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
HRCT1 | Histidine rich carboxyl terminus 1 | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/2419/ihc_cell_selected_60x60.jpg) | ![](/images/2419/6368_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL6 | Interleukin 6 (interferon, beta 2) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| ![](/images/23406/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/23406/54889_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
INHBB | Inhibin, beta B | Cancer-related genes Predicted secreted proteins
| ![](/images/35386/ihc_selected_60x60.jpg) | ![](/images/49218/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/35386/78325_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
IRX6 | Iroquois homeobox 6 | Transcription factors
| ![](/images/18332/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18332/43211_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
KANK4 | KN motif and ankyrin repeat domains 4 | | ![](/images/14030/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14030/31231_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42434/134323_B_1_7_rna_selected_60x60.jpg) | Tissue enhanced |
KIF25 | Kinesin family member 25 | | ![](/images/46153/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46153/104766_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
KLB | Klotho beta | Predicted membrane proteins
| ![](/images/21136/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21136/48771_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
MARC1 | Mitochondrial amidoxime reducing component 1 | Mitochondrial proteins
| ![](/images/28702/ihc_selected_60x60.jpg) | ![](/images/28702/if_selected_60x60.jpg) | | ![](/images/28702/64703_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
MDFI | MyoD family inhibitor | | ![](/images/49973/ihc_selected_60x60.jpg) | ![](/images/49973/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/49973/112170_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
MEDAG | Mesenteric estrogen-dependent adipogenesis | | ![](/images/53763/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/53763/128314_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
MINOS1-NBL1 | MINOS1-NBL1 readthrough | Predicted membrane proteins Predicted secreted proteins
| ![](/images/59930/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/59930/133195_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
MMP19 | Matrix metallopeptidase 19 | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| ![](/images/12845/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12845/30287_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
MT1A | Metallothionein 1A | Cancer-related genes
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2161/5772_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
MYOC | Myocilin, trabecular meshwork inducible glucocorticoid response | Disease related genes Plasma proteins Predicted secreted proteins
| ![](/images/27364/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/27364/58505_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
NMB | Neuromedin B | Predicted secreted proteins
| ![](/images/19302/ihc_selected_60x60.jpg) | ![](/images/19302/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/19302/43014_B_9_4_rna_selected_60x60.jpg) | Tissue enhanced |
NPR1 | Natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) | Enzymes FDA approved drug targets Predicted membrane proteins
| ![](/images/31087/ihc_selected_60x60.jpg) | ![](/images/31087/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/31087/71781_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
NXNL1 | Nucleoredoxin-like 1 | | ![](/images/42010/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42010/90380_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
PALM2-AKAP2 | PALM2-AKAP2 readthrough | | ![](/images/58905/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/58905/139658_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |
PDE3B | Phosphodiesterase 3B, cGMP-inhibited | Enzymes Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9497/31482_A_1_6_rna_selected_60x60.jpg) | Tissue enhanced |
PLXNA4 | Plexin A4 | Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/52141/140902_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
PPP1R1A | Protein phosphatase 1, regulatory (inhibitor) subunit 1A | | | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/7811/144175_B_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
PRKAR2B | Protein kinase, cAMP-dependent, regulatory, type II, beta | | | ![](/images/8421/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/8421/21824_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
PROKR1 | Prokineticin receptor 1 | G-protein coupled receptors Predicted membrane proteins
| ![](/images/29396/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/29396/61550_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
PTX3 | Pentraxin 3, long | Plasma proteins Predicted secreted proteins
| ![](/images_static/rna_center.gif) | ![](/images/22226/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
RASL10B | RAS-like, family 10, member B | | ![](/images/57092/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/57092/140694_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
RP11-599B13.6 | Uncharacterized protein | Predicted membrane proteins
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
SEMA3G | Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3G | Predicted secreted proteins
| ![](/images/1761/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/1761/7364_B_7_7_rna_selected_60x60.jpg) | Tissue enhanced |
SHOX2 | Short stature homeobox 2 | Transcription factors
| ![](/images_static/rna_center.gif) | | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
SLC19A3 | Solute carrier family 19 (thiamine transporter), member 3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| ![](/images/38898/ihc_selected_60x60.jpg) | ![](/images/38898/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/38898/80786_B_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
SMIM3 | Small integral membrane protein 3 | Predicted membrane proteins
| ![](/images/56610/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/56610/131803_B_9_8_rna_selected_60x60.jpg) | Tissue enhanced |
SNCG | Synuclein, gamma (breast cancer-specific protein 1) | | | ![](/images/40581/if_selected_60x60.jpg) | ![](/images/1452/ihc_cell_selected_60x60.jpg) | ![](/images/1452/4643_B_7_6_rna_selected_60x60.jpg) | Tissue enhanced |
SOD3 | Superoxide dismutase 3, extracellular | Enzymes Plasma proteins Predicted secreted proteins
| ![](/images/42110/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42110/91153_B_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
SOX18 | SRY (sex determining region Y)-box 18 | Disease related genes Transcription factors
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
TCF15 | Transcription factor 15 (basic helix-loop-helix) | Transcription factors
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/50998/148399_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
THRSP | Thyroid hormone responsive | | ![](/images/40642/ihc_selected_60x60.jpg) | ![](/images/40642/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/40642/90389_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
TMEM132C | Transmembrane protein 132C | Predicted membrane proteins
| ![](/images/15984/ihc_selected_60x60.jpg) | | ![](/images_static/rna_center.gif) | ![](/images/15633/36690_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
TNMD | Tenomodulin | Predicted membrane proteins
| ![](/images/55634/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/55634/131621_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
TNN | Tenascin N | Plasma proteins Predicted secreted proteins
| ![](/images/10907/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/10907/27089_B_4_5_rna_selected_60x60.jpg) | Tissue enhanced |
TWIST1 | Twist family bHLH transcription factor 1 | Cancer-related genes Disease related genes Transcription factors
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
TWIST2 | Twist family bHLH transcription factor 2 | Disease related genes Transcription factors
| ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images_static/na_center.gif) | Tissue enhanced |
WNT11 | Wingless-type MMTV integration site family, member 11 | Predicted secreted proteins
| ![](/images/50101/ihc_selected_60x60.jpg) | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/50101/118000_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |